Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. Pratz KW, et al. Among authors: vorobyev v. J Clin Oncol. 2022 Mar 10;40(8):855-865. doi: 10.1200/JCO.21.01546. Epub 2021 Dec 15. J Clin Oncol. 2022. PMID: 34910556 Free PMC article. Clinical Trial.
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, Levin MD, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Niemann CU, Kater AP. Munir T, et al. Among authors: vorobyev v. J Clin Oncol. 2023 Jul 20;41(21):3689-3699. doi: 10.1200/JCO.22.02283. Epub 2023 Jun 6. J Clin Oncol. 2023. PMID: 37279408 Free PMC article.
[Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma].
Baryakh EA, Misyurina AE, Kovrigina AM, Obukhova TN, Gemdzhyan EG, Vorobyev VI, Mangasarova YK, Polyakov YY, Magomedova AU, Klyasova GA, Misyurin VA, Yatsyk GA, Shevelev AA, Kostina IE, Vorobyev AI, Kravchenko SK. Baryakh EA, et al. Among authors: vorobyev vi, vorobyev ai. Ter Arkh. 2015;87(8):77-85. doi: 10.17116/terarkh201587877-85. Ter Arkh. 2015. PMID: 26824820 Russian.
[Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia].
Nesterova ES, Kravchenko SK, Mangasarova YK, Baryakh EA, Misyurina AE, Vorobyev VI, Plastinina LV, Chernova NG, Kovrigina AM, Obukhova TN, Klyasova GA, Shevelev AA, Kostina IE, Gemdzhian EG, Gaponova TV, Vorobyev AI. Nesterova ES, et al. Among authors: vorobyev vi, vorobyev ai. Ter Arkh. 2016;88(7):62-71. doi: 10.17116/terarkh201688762-71. Ter Arkh. 2016. PMID: 27459617 Clinical Trial. Russian.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, Koh Y, Maisnar V, Karlin L, Pavic M, Campana F, Le Guennec S, Menas F, van de Velde H, Richardson PG. Bringhen S, et al. Among authors: vorobyev v. Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29. Leuk Res. 2021. PMID: 33839618 Free article. Clinical Trial.
[Therapy for Burkitt's lymphoma according to the BL-M-04 protocol: 12-year experience].
Baryakh EA, Tyurina NG, Vorobyev VI, Gemdzhyan EG, Mangasarova YK, Klyasova GA, Kovrigina AM, Obukhova TN, Zvonkov EE, Vernyuk MA, Chervontseva AM, Polyakov YY, Misyurina АЕ, Valiev TT, Zherebtsova VA, Magomedova AU, Galstyan GM, Yatskov KV, Nesterova ES, Vorobyev AI, Kravchenko SK. Baryakh EA, et al. Among authors: vorobyev vi, vorobyev ai. Ter Arkh. 2015;87(7):4-14. doi: 10.17116/terarkh20158774-14. Ter Arkh. 2015. PMID: 26390720 Russian.
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Mateos MV, et al. Among authors: vorobyev v. Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23. Lancet Haematol. 2020. PMID: 32213342 Clinical Trial.
280 results